Cutaneous and Ocular Toxicology最新文献

Objectives: This study was to investigate the effects of atropine sulphate eye drops (ASED)on the development of partial systems in young rats and their toxic reactions following repeated eye-drop administration over a period of 40 days.

Methods: SD rats of 20 days old were randomly assigned to control group, 0.01, 0.02, and 0.04% ASED groups, with 60 females and 25 males per group. ASED was given by eye drops from PND₂₁ onwards and normal saline was given in the control group at 10 μL/eye once a day for 40 days, in both right and left eyes. Rats of ASED groups were instilled with eye drops at the 10 μL/day per eye, from postnatal day 21 (PND₂₁) to PND₆₀ for 40 consecutive days. The clinical observation, body weight, food intake, physical development, physiological development, reproductive development, ophthalmic examination, intraocular pressure, and axial length of the rats were examined during the study period.

Results: ASED at concentrations of 0.01, 0.02, 0.04%, dose levels of 0.002, 0.004, 0.008 mg/day per rat, had no toxicological effects on the clinical observation, body weight, food intake, physical development, physiological development, reproductive development, ophthalmic examination, intraocular pressure, and axial length in rats.

Conclusion: The no-observed-adverse-effect-level (NOAEL) of ASED in young SD rats equivalent to human over 2 years old was 0.008 mg/day at a concentration of 0.4 mg/mL.

Purpose: To assess changes in the thickness of macular sublayers in individuals taking hydroxychloroquine (HCQ) without any evident toxicity and to review the relevant literature.

Methods: This prospective case-control study examined 47 adults on HCQ without evident toxicity on spectral-domain optical coherence tomography (SD-OCT) and visual field tests, as well as 25 healthy controls. Macular thickness in different sublayers was measured using SD-OCT. The thickness of combination layers and the variability of sublayers were also recorded. Data were compared between the case and control groups, and the correlation between cumulative HCQ use and outcome measures was analysed.

Results: The average age of participants in the case and control groups was 45.6 ± 9.3 and 46.8 ± 11.7 years, respectively (p = 0.831). The percentage of female participants was 91.5% in the case group and 84.0% in the control group (p = 0.927). In the case group, the average duration of HCQ use was 5.1 ± 5.2 years, with a mean cumulative dose of 301 ± 365 g. No significant differences were found in the visual field mean deviation or pattern standard deviation between patients with HCQ use of <5-years vs. ≥5-years. Additionally, there were no statistically significant differences in various retinal thickness measurements between the case and control groups. However, a significant association was observed between the cumulative dose of HCQ and the thickness of the outer retinal layer (ORL) in both the outer (r = 0.344; p = 0.032) and inner Early Treatment Diabetic Retinopathy Study (ETDRS) macular rings (r = 0.303; p = 0.061).

Conclusions: No significant difference in macular sublayer thickness was found between patients taking HCQ without evident toxicity and the control group. A weak direct association was observed between the cumulative dose of HCQ and the ORL thickness. These findings suggest that analysing macular sublayer thickness may not be useful in detecting the earliest signs of presumed HCQ toxicity in individuals without classical sign of toxicity on qualitative SD-OCT or visual field test.

The utilisation of heavy metal-based nanoparticles in cosmetic products has been steadily increasing because of their extraordinary physicochemical properties and benefits. In this thorough review, we will delve into the various types of nanoparticles, such as green nanoparticles, metallic nanoparticles, and carbon-based nanoparticles, with a special focus on heavy metal-based nanoparticles. These heavy metal-based nanoparticles exhibit exceptional physical and mechanical properties, making them suitable materials for cosmetic and personal care products. Silver nanoparticles effectively treat acne and have strong antimicrobial properties, while gold nanoparticles have anti-ageing and anti-inflammatory properties. ZnO and TiO2 nanoparticles are commonly used in sunscreens as ultraviolet (UV) filters to protect against ultraviolet-A (UVA) and ultraviolet-B (UVB) radiation. Certain metals like nickel, chromium, and cobalt are major allergens, frequently causing contact dermatitis and allergic reactions in sensitive individuals. Extensive use of materials such as cadmium, lead, mercury, and arsenic (metalloid) in cosmetics poses long-term health risks, including carcinogenicity, neurotoxicity, and organ damage. The utilisation of herbal extracts containing heavy metals in cosmetics further improves the effectiveness of personal care products due to their antioxidant properties. Consumer awareness and regulatory concerns, especially among those with metal allergies, are crucial for understanding the potential risks associated with heavy metal-containing cosmetics. Looking ahead, future research efforts should concentrate on the development of safer, non-toxic, natural nanomaterials and biocompatible alternatives to heavy metal-based nanoparticles.

Objective: To determine the predictive factors for severity in prostaglandin-associated periorbitopathy (PAP) using an objective grading system.

Methods: The study included patients diagnosed with glaucoma or ocular hypertension who had used a topical prostaglandin analog (PGA) unilaterally for at least three months. Clinical characteristics and PAP signs were compared based on the types of PGAs used. The severity of PAP signs was categorised according to an objective grading system. Univariate and multivariate logistic regression analyses were performed to identify risk factors for different grades of PAP.

Results: Among the 86 patients included in the study, 24 (27.9%) used bimatoprost, 35 (40.7%) used latanoprost, and 27 (31.4%) used travoprost. The most commonly observed feature of PAP was orbital fat atrophy (48.8%), followed by deepening of the upper eyelid sulcus (38.4%), involution of dermatochalasis (32.6%), and enophthalmos (26.7%). Fifty-eight patients (67.4%) exhibited at least one periorbital change associated with PGA use. Multivariate logistic regression analysis revealed that age >60 years (p < 0.05), the use of bimatoprost (p < 0.05) and travoprost (p < 0.05), and PGA therapy duration >1 year (p < 0.05) were independent risk factors for higher grades of PAP.

Conclusion: Older age, longer duration of PGA therapy, and the use of bimatoprost and travoprost were significant and independent predictors of severe PAP in patients with glaucoma. Patients with these risk factors should be identified and managed to prevent the development of severe PAP.

Purpose: To investigate the potential effects of systemic fingolimod treatment on parameters of the anterior segment of the eye and tear film function tests in patients with multiple sclerosis (MS).

Methods: Forty-eight eyes of 24 individuals who were started on systemic fingolimod treatment for relapsing-remitting MS were prospectively enrolled in this study. Patients underwent examinations immediately before initiation of systemic fingolimod treatment, and at the first and sixth months of treatment. Anterior segment parameters were measured using Sirius Topography. The Schirmer-I test and tear break-up time (TBUT) were recorded during follow-up. Retinal thickness was also analyzed using spectral-domain optical coherence tomography (SD-OCT).

Results: There was no statistically significant difference in retinal thickness measurements between follow-up visits. The central corneal thickness, keratometric values, anterior chamber depth, aqueous humor depth, iridocorneal angle, horizontal anterior chamber tilt and anterior chamber volume values remained similar during follow-up. The Schirmer-I test value was 15.10 ± 2.65 mm at the zeroth month and 17.03 ± 3.61 mm at the sixth month (p = 0.044). The mean TBUT was significantly higher at the six-month visit compared to baseline and the one-month visit (p_0-6 < 0.001, p_1-6 < 0.001), but there was no statistically significant difference between baseline and month 1 (p_0-1 = 0.419).

Conclusion: Systemic use of fingolimod may increase Schirmer I test and TBUT values in MS patients without altering other anterior segment parameters within 6 months.

Purpose: This study examined a plant extract (PE) foundation's safety, antioxidant and protective properties. To offer a scientific foundation for the viability of creating 'skincare makeup' and improve the comprehension of cosmetic compositions' efficacy evaluations.

Methods: Cellular assays tested six different concentrations (up to 5%) of the PE for cell viability levels and reactive oxygen species (ROS) levels of human immortalised epidermal cells (HaCaTs). The identified non-cytotoxic concentration (0.5% PE) was then tested by gene assays. A commercial foundation containing 0.5% PE (PEF0.5) was tested for safety, skin protective effectiveness, and user satisfaction.

Results: Compared to the control groups, 0.5% PE had a significant inhibitory effect on the expression level of MMP-1 but promoted the expression of COL1A1, COL3A1, ELN, and AQP3. PEF0.5 significantly (p < 0.05) reduced wrinkles and transepidermal water loss (TEWL) while improving hydration, glossiness, and elasticity for 14 and 28 days. Interestingly, sebum was reduced by PEF0.5 at 28 days without any negative consequences for 28 days. No significant (p > 0.05) differences were detected in the foundation's effectiveness and usability.

Conclusion: Applying PEF0.5 for 28 days may improve the skin barrier function, as indicated by skin TEWL, hydration, wrinkle, elasticity, and sebum content, without any adverse effects.

Background: Test methods to inform hazard characterization and labeling of pesticides to protect human health are typically conducted using laboratory animals, and for skin irritation/corrosion the rabbit Draize test is currently required by many regulatory agencies. Although the Draize test is generally regarded to provide protective classifications for human health, new approach methodologies (NAMs) have been developed that offer more human relevant models that circumvent the uncertainty associated with species differences that exist between rabbits and humans. Despite wide applicability and use of these test methods across a broad range of chemicals, they have not been widely adopted for testing pesticides and pesticidal formulations. One of the barriers to adoption of these methods in this sector is low concordance with results from the Draize rabbit test, particularly for chemicals within the mild to moderate irritation spectrum.

Methods: This review compares and contrasts the extent to which available models used in skin irritation testing mimic the anatomy and physiology of human skin, and how each aligns with the known key events leading to chemically-induced adverse skin irritation and corrosion. Doing so fully characterizes the human relevance of each method.

Results: As alternatives to the rabbit Draize test, several protocols using ex vivo, in chemico, and in vitro skin models are available as internationally harmonized test guidelines. These methods rely on a variety of models of human skin, including excised rodent skin, synthetic biochemical models of barrier function, cell culture systems, and reconstructed human tissue models. We find these models exhibit biological and mechanistic relevance aligned with human skin irritation responses. Further, recent retrospective analyses have shown that the reproducibility of the Draize test is less than 50% for mild and moderate responses, with many of the replicate predictions spanning more than one category (e.g., a moderate response reported in one study followed by a non-irritant response reported in another study).

Conclusions: Based on this comparative evaluation, we recommend top-down and bottom-up testing strategies that use the most human relevant in vitro test methods for skin irritation and corrosion classification of pesticides and pesticide formulations. To further discriminate among mild and non-irritant formulations, optimization of a cytokine release protocol and subsequent analyses of reference formulation test results is recommended.

Objective: In recent years, the frequency of use of biological agents in the treatment of many dermatological diseases has been increasing. While effective, these treatments may carry the risk of hepatitis B virus (HBV) reactivation, particularly in patients with underlying or resolved HBV infection. Data on the risk of reactivation—especially with newer IL-23 antagonists that treat psoriasis vulgaris such as risankizumab and guselkumab, and IL-17 antagonists such as ixekizumab and secukinumab—remain limited. The aim of this study was to investigate HBV seroprevalence in patients with psoriasis using biological drug therapy and to investigate the frequency of reactivation and the importance of prophylactic treatment in this patient group at risk of HBV reactivation.

Methods: This retrospective study included 219 patients (aged 18-92) with psoriasis vulgaris who were treated with at least one biological drug treatment for at least 3 months at Dicle University Dermatology Clinic between 1 January 2018 and 30 June 2024. HBV serological markers (HBsAg, anti-HBcIgG, anti-HBs) and laboratory test results were evaluated. Patients were divided into five groups based on HBV serological: natural immune, chronic HBV infection, isolated anti-HBcIgG positivity, vaccinated and susceptible. These serological tests were repeated every 6 months during follow-up. Patients who did not meet the above-mentioned criteria or had incomplete test results were excluded from the study. Screening for hepatitis B reactivation was performed only in those with a positive anti-HBc IgG test who were at risk of reactivation. This was defined as either: Those who had a positive HBV DNA test prior to biological treatment and had an increase of >1 log10İU/mL in HBV DNA titre during biological treatment use; or those who initially tested negative for HBV DNA prior to starting biological treatment but became HBV DNA–positive during treatment were considered to have HBV reactivation.

Results: Of the 219 psoriasis vulgaris patients, 102 (46.6%) females and 117 (53.4%) males. The distribution biological agents uses was as follows: 87 (39.7%) secucinumab, 29 (13.2%) ixekizumab, 47 (21.5%), guselkizumab, and 56 (25.6%) risankizumab. Patients were categorized into five (5) groups based on HBV serology and among these groups, 46 (21%) patients (10 with secucinumab and risakizumab, 12 with ixekizumab, and 14 with guselkizumab) were found to be at risk of hepatitis B reactivation (anti-HBc IgG test positive). It was observed that 40 (86.96%) of these 46 patients at risk of hepatitis B reactivation used prophylaxis, and no reactivation developed. No significant ALT or AST elevation was detected in all patients during their biological treatment

Conclusion: IL-23 antagonist such as rizankizumab and guzelkumab, as well as IL-17 antagonists like secukinumab and ixekizumab, have been reported to carry a risk of

Purpose: Photoaging is characterised by cutaneous changes caused by exposure to ultraviolet light over time. Quercetin is a bioflavanoid with antioxidant, antineoplastic, and anti-inflammatory effects. This study investigated the therapeutic effects of topical quercetin on photoaging, a phenomenon not previously studied in ultraviolet A (UVA)-induced photoaging.

Methods: A total of 40 rats were randomly categorised into 5 groups, each comprising 8 rats. A photoaging model was induced by applying UVA to the dorsal region of all rats, except for the negative control group. Topical 0.1% retinoic acid was applied to one UVA group, topical 0.3% quercetin to another UVA group, and both agents were applied in combination to yet another UVA group 5 days a week for 8 weeks. Subsequently, wrinkle values were measured, reactive oxygen species (ROS) and matrix metalloproteinase-1 (MMP-1) levels were analysed, and histopathological parameters were examined.

Results: The wrinkle value of the UVA group was found to be significantly higher than that of the UVA + Quercetin group. Collagen damage was lower in the UVA + Quercetin group than in the UVA group, although this difference was not statistically significant. Compared with the UVA + Retinoic Acid group, the UVA + Quercetin group exhibited a more significant decrease in inflammation. MMP-1 values were considerably higher in the UVA + Retinoic Acid and UVA + Quercetin + Retinoic Acid groups as well as in the UVA + Quercetin group compared with the control and UVA groups.

Conclusion: The present study showed that quercetin can be utilised in the treatment of photoaging, especially when combined with retinoic acid.

Purpose: Cosmetic botulinum toxin A (BoNT-A) injections are increasing worldwide. Adverse effects need to be evaluated in more detail for BoNT-A regulations. This study aims to assess the anticholinergic effect of BoNT-A on accommodation amplitude (AA) after upper face application.

Methods: Twenty patients aged between 20 and 45 years were recruited in this prospective, interventional study. Abobotulinum toxin A of 500 units was diluted with 3 ml saline and injected into the forehead, glabellar and periorbital area. AA was measured with both the push-up and minus-lens techniques before and after two weeks of the injections. T-test for normally distributed variables was applied for the comparison of the results.

Results: The study group comprised 18 women and 2 men with a mean age of 33.9 ± 8.59. AA decreased significantly after two weeks of the injection. In the push-up test, AA was 9.18 ± 4.72 D before BoNT-A injection and decreased to 7.11 ± 3.02 D after the injection (p < 0.001). In the minus lens test, AA reduced from 5.86 ± 2.24 D to 5.24 ± 2.06 D after BoNT-A injection (p < 0.001). Refraction did not change in any of the participants.

Conclusion: The present study showed that cosmetic upper face BoNT-A injections reduced AA. However, this reduction did not result in any significant symptomatic effects in the patients. These findings suggest that while BoNT-A injection has a measurable impact on the ciliary muscle or its parasympathetic innervation, it may not lead to noticeable clinical outcomes.